Evidence map›Paper›PMID 40696604›Full record

ArticleMedicine2025

Prediction of biomarkers for brain metastasis in nonsmall cell lung cancer based on transcriptome sequencing.

Liangting Tan, Xuesong Xiang, Qiyi Qian, Qikun Zhang, Qiuran Xu, Wenhong Qiu, Xiaoliang Zheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liangting TanZhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, China.
Xuesong XiangDepartment of Immunology, Jianghan University, School of Medicine, Wuhan, China.
Qiyi QianZhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, China.
Qikun ZhangZhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, China.
Qiuran XuZhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
Wenhong QiuDepartment of Immunology, Jianghan University, School of Medicine, Wuhan, China.
Xiaoliang ZhengZhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, China.ORCID 0000-0002-7955-7455

Funding

Key Research and Development Select Projects of Zhejiang Provincial Department of Science and Technology 2020C03008Science Foundation of Zhejiang Province LTGY23H160032
6 · The paper itself

Abstract

backgroundLung cancer is one of the most prevalent malignancies worldwide, and the metastasis of nonsmall cell lung cancer often leads to rapid deterioration of patient conditions, with brain metastasis (BM) being the most detrimental. The mechanisms underlying lung cancer brain metastasis remain incompletely understood.

objectiveThis study aimed to elucidate the molecular mechanisms of lung cancer brain metastasis and identify potential biomarkers and therapeutic targets.

methodsThe high invasiveness of H1975-BM51 cells was verified using Western blotting, cell invasion assays, and the establishment of an nonsmall cell lung cancer brain metastasis mouse model. Transcriptome sequencing of H1975 and H1975-BM51 cells was conducted, followed by Least Absolute Shrinkage and Selection Operator regression and single-gene Gene Set Enrichment Analysis to screen key genes. Quantitative real-time PCR and Western blotting were employed to detect the expression levels of the AGO3 gene in H1975-BM51 cells.

resultsTranscriptomic analysis revealed that the AGO3 gene contributes to lung cancer brain metastasis by negatively regulating hormone metabolic processes. Compared with parental H1975 cells, both mRNA and protein expression levels of AGO3 were significantly upregulated in highly invasive H1975-BM51 cells.

conclusionThis study identifies AGO3 as a potential biomarker and therapeutic target for lung cancer brain metastasis.

Indexed as

Biomarkers, TumorBrain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiceTranscriptomeBiomarkers, Tumorbiomarkersbrain metastasisLASSO regressionnonsmall cell lung cancertranscriptome sequencing

Identifiers

PMID40696604
PMCPMC12282759

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.